Latest Secondary Hyperparathyroidism (SHPT) News
Panel focuses on diagnosing and testing of CKD-MBD and treatment of the CKD-MBD that emphasizes decreasing phosphate, maintaining calcium, and addressing elevated PTH in adults with CKD stage G3a to G5.
Abnormal calcium-phosphate metabolism appears to be an important pathogenic factor in the development of vascular calcification in patients with chronic kidney disease.
In patients with stage 5 chronic kidney disease, lupus anticoagulant and combined thrombophilia occur more frequently in those with versus without calciphylaxis, case-control study shows.
iPTH significantly correlated with measures of diastolic dysfunction in patients with non-dialysis chronic kidney disease.
Patients with high alkaline phosphatase prior to PTx should be treated aggressively after surgery to prevent postoperative hypocalcemia, researchers conclude.
In 2 studies, parathyroid hormone (PTH) values 20 minutes after parathyroidectomy predicted PTH levels for 5 years.
In a study, intact parathyroid hormone levels below 60 and above 1500 pg/mL were associated with nearly double the risk of all-cause mortality.
In a small study, more than half of patients with secondary hyperparathyroidism had a greater than 25% drop in parathyroid hormone levels following ethanol injection therapy.
Nearly 86% of diabetic nephropathy patients from an Egyptian outpatient center had elevated iPTH levels.
Hypocalcemia developed in 58.3% of study participants within the first 16 weeks and, in most cases, resolved within 14 days with no changes in treatment.
Patients reported less skin itching, joint pain, and muscle weakness after surgery.
ESRD patients with SHPT undergoing surgery had a 26% lower risk for all-cause mortality compared with medical management.
Secondary hyperparathyroidism may have a detrimental effect on successful arteriovenous fistula creation, researcher says.
In a pilot study, investigators observed no harmful effects from etelcalcetide injection, and 5 of 10 of patients had a greater than 50% decline in PTH levels.
Therapy with paricalcitol alone achieved the greatest decline in intact parathyroid hormone among hemodialysis with secondary hyperparathyroidism.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- Lymphoceles: A Contemporary Review and an Approach for Prevention
- Anticoagulants Tied With Stroke, Hemorrhage in CKD
- Coronary Artery Calcification Risk Factors in CKD Identified
- Pulmonary Hypertension Linked With Worse Prognosis in CKD, ESRD
- Adverse Prostate Cancer Pathology Accurately Predicted With MRI